Fig. 4
From: Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice
Adoptive transfer of TCRAβ-Tregs increase Treg homing to brain and Treg function. A Representative flow cytometric gating strategy for quantification of total Treg frequencies (CD4+ CD25+ FoxP3+). B Frequencies of Tregs in spleen, lymph node, blood, and brain in APP/PS1 mice adoptively transferred with three, weekly doses of 1 × 106 TCRAβ-Tregs, polyclonal Tregs (Treg) or EV-Tregs (TCR−−-Tregs electroporated with empty plasmid vector) (n = 5-6) C Representative PET images of APP/PS1 brains after adoptive transfer of 18F-FDG radiolabeled polyclonal Tregs (Treg) or TCRAβ-Tregs and their biodistribution evaluated at 0.5, 2, and 6 h. D Quantitation of radioactivity from PET images of 18F-FDG radiolabeled Tregs or TCRAβ-Tregs in the brain acquired at 0.5, 2, 4, and 6 h (n = 3). E Suppressive capability of peripheral Tregs from APP/PS1 mice that were untreated or treated with TCRAβ-Tregs, polyclonal Tregs (Treg) or EV-Tregs (TCR−− -Tregs electroporated with empty plasmid vector). Linear regression analysis indicates r.2 > 0.90, p < 0.001 for all treatment groups. Table contains p-values for slopes and intercepts of compared linear regression analysis (n = 3). Flow cytometric analysis of; F MHC-Aβ-tetramer positive Tregs (CD4+ CD25+ Aβ-Tetramer+) and G MHC-Aβ-tetramer positive CD4+ CD25-Aβ-Tetramer + splenocytes stimulated with Aβ protein and low dose IL-2, (n = 5–6). B, F Data presented as mean ± SEM. One-way ANOVA followed by Turkey’s post hoc test was used to determine significant differences between experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001